Jensen Gregory, Morrill Christian, Huang Yu
Department of Biological Engineering, Utah State University, Logan, UT, 84322, USA.
Acta Pharm Sin B. 2018 Sep;8(5):756-766. doi: 10.1016/j.apsb.2018.03.006. Epub 2018 Mar 21.
Tissue engineering and the tissue engineering model have shown promise in improving methods of drug delivery, drug action, and drug discovery in pharmaceutical research for the attenuation of the central nervous system inflammatory response. Such inflammation contributes to the lack of regenerative ability of neural cells, as well as the temporary and permanent loss of function associated with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and traumatic brain injury. This review is focused specifically on the recent advances in the tissue engineering model made by altering scaffold biophysical and biochemical properties for use in the treatment of neurodegenerative diseases. A portion of this article will also be spent on the review of recent progress made in extracellular matrix decellularization as a new and innovative scaffold for disease treatment.
组织工程和组织工程模型已显示出有望改善药物递送、药物作用及药物发现方法,用于制药研究以减轻中枢神经系统炎症反应。这种炎症会导致神经细胞再生能力缺失,以及与阿尔茨海默病、帕金森病和创伤性脑损伤等神经退行性疾病相关的功能暂时和永久性丧失。本综述特别关注通过改变支架生物物理和生化特性用于治疗神经退行性疾病的组织工程模型的最新进展。本文还将花一部分篇幅回顾细胞外基质去细胞化作为一种用于疾病治疗的新型创新支架所取得的最新进展。